Page 196 of 400: studies 1,951 to 1,960 of 3,999, newest first. Back to the serotonin overview
BMJ March 20, 2026 Jeffrey K Aronson 1 citation
Psychedelic drugs produce effects on the mind that manifest as an apparent expansion of consciousness often accompanied by hallucinations. Psychedelics, which act as agonists at serotonin 5-HT2A receptors in the brain, include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (tryptamine derivatives), mescaline (a phenethylamine derivative), and lysergic acid diethylamide...
International Journal of Innovative Technologies in Social Science March 19, 2026 Anna Komarczewska, Michał Kociński, Patryk Iglewski et al.
Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocybin-assisted therapy has recently...
JAMA Psychiatry March 18, 2026 Zachary J. Williams, Hannah Barnett, Balázs Szigeti 10 citations
Importance: Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions. Because PAT is effectively always open label, treatment results should be compared with those of open-label traditional antidepressants (TADs), so potential benefits associated with patients knowing their treatment is equal between...
Cureus March 17, 2026 Ngo Cheung
Hypochondriacal obsessive-compulsive disorder (OCD) combines intrusive health anxieties with compulsive reassurance seeking and often resists high-dose selective serotonin reuptake inhibitors and cognitive-behavioural therapy. Interest has shifted toward glutamatergic agents that mimic ketamine's rapid synaptic effects. A 34-year-old woman endured two years of recurrent fear of serious...
Journal of the American Academy of Child & Adolescent Psychiatry March 17, 2026 Yunjia Liu, Qiang Wang
Adolescent major depressive disorder (MDD) is a leading cause of disability worldwide and a major, modifiable risk factor for suicide, which remains the second leading cause of death in this age group.1 For 30% to 50% of patients who fail to achieve remission despite multiple treatment steps, the clinical and psychosocial consequences are substantial.2 Although selective serotonin-reuptake...
Frontiers in Pharmacology March 16, 2026 Alessandra Linardi, Ariadiny Lima Caetano, Rodrigo Portes Ureshino
psychiatric disorders, beta-carbolines, trace amine, phosphoproteomics, social hierarchy. Scientific interest in psychedelic substances has re-emerged, offering new perspectives on the treatment of neuropsychiatric and neurological disorders.Historically, psychedelics have been associated with a wide spectrum of positive and negative effects, encompassing ritualistic and spiritual use,...
Clinics and practice March 13, 2026 Alessandro Guffanti, Matteo Leonardi, Natascia Brondino et al.
Major depressive disorder (MDD) is a leading cause of disability worldwide and contributes significantly to the global burden of disease. Recent data show an increasing prevalence of treatment-resistant depression (TRD). Patients with autism spectrum disorder (ASD) often exhibit MDD as a comorbidity and it is often resistant to conventional treatments. ASD determines emotional dysregulation and...
Child and Adolescent Psychiatry and Mental Health March 13, 2026 Marc-Antoine Crocq, Philippe Auby
Aims The recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology. Methods We reviewed recent literature, regulatory documents, and clinical trial...
Schizophrenia Research March 13, 2026 Michel Sabé, Paul Grof, Nathan Sackett et al. 1 citation
Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....
Journal of Psychopharmacology March 13, 2026 Francisco Moreno, Katja Ehrmann Allen, Christopher B. Wiegand et al. 3 citations
BACKGROUND: Current treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. AIMS: This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses...